Sealantium Medical

Tissue Sealants and Hemostatic Agents

Health Tech & Life Sciences
Active
Series B Rosh Haayin Founded 2011
Total raised
$11.6M
Last: Series B 2018-10
Stage
Series B
Founded
2011
Headcount
6
HQ
Rosh Haayin
Sector
Health Tech & Life Sciences

About

Sealantium Medical is a biosurgery company focused on the development of proprietary next generation tissue sealants and hemostatic agents for patients undergoing surgery.

The company's flagship product is the sFilm-FS™, which comprises a biodegradable and biocompatible, non-permeable polymeric film containing Fibrin Sealant. This polymeric film uniquely enables sealing capabilities alongside accelerating fluid coagulation and site adhesion. As a result of this novel mechanism of action, substantially less Fibrin Sealant is needed lowering costs and accelerating speed of sealing (2min) for improved performance.

Successful preclinical data has demonstrated efficacy and usability of the sFilm-FS. Promising early clinical results show safety and a faster performance in controlling liver bleeding during surgery than the market leading product.

Funding history · 1 round · $11.6M total

2018-10
Series B $10.0M

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Sealantium Medical's primary focus?
Sealantium Medical is a biosurgery company that develops proprietary next-generation tissue sealants and hemostatic agents for surgical patients.
What is the name of Sealantium Medical's flagship product?
Sealantium Medical's flagship product is the sFilm-FS™.
What is the composition and function of the sFilm-FS™?
The sFilm-FS™ is a biodegradable and biocompatible, non-permeable polymeric film containing Fibrin Sealant. It provides sealing capabilities, accelerates fluid coagulation, and promotes site adhesion, requiring less Fibrin Sealant for faster sealing.
What clinical results has Sealantium Medical observed for sFilm-FS™?
Promising early clinical results for sFilm-FS™ have demonstrated safety and faster performance in controlling liver bleeding during surgery compared to the market-leading product.
When did Sealantium Medical complete its Phase I/II clinical study?
Sealantium Medical announced the completion of its Phase I/II clinical study on June 22, 2023.
When was Sealantium Medical founded?
Sealantium Medical was founded in January 2011.
What was Sealantium Medical's most recent funding round?
Sealantium Medical's most recent funding was a Series B round in October 2018, led by Biotech Alliances International. For a full financing history, please refer to startupim.
Did Sealantium Medical receive any grants?
Yes, Sealantium Medical received a grant of $1,572,319 from the IIA in April 2018.
How many employees does Sealantium Medical currently have?
Sealantium Medical currently has 6 employees.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Materials & SubstancesPolymers
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

first-aidmedical-technologiessurgerybiotechnologybiodegradablepolymershospitalscritical-caretissue-regeneration